Xospata 40mg (Gilteritinib Tablet) 40mg

Xospita 40mg (gilteritinib) tablets are prescribed for adults with certain blood cancers. This oral therapy helps manage disease progression in FLT3-mutated acute myeloid leukemia. A convenient once-daily option for targeted treatment at home. Store at room temperature.

Strength

40mg

Pack Size

84s

Storage

Ambient

Manufacturer / TM Owner

Astellas

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Xospita 40mg is used to treat adults with relapsed or refractory acute myeloid leukemia (AML) that has a FLT3 mutation. It is prescribed when previous treatments have not been effective. The medication works by targeting specific genetic changes in cancer cells to slow disease progression. It is not a cure but helps manage symptoms and extend remission periods.

Side Effects

Common effects include fatigue, nausea, and changes in taste. Some people report dizziness or joint pain while taking this medication. These effects vary in intensity and may lessen over time. Regular monitoring by a healthcare provider is recommended to manage any discomfort.

Precautions & Warnings

Keep Xospita 40mg tablets in their original packaging at room temperature, away from moisture and direct sunlight. Store securely out of reach of children and pets. Do not use if the packaging is damaged or the tablets appear altered. Always follow your doctor’s instructions for handling and disposal.

Avoid Interactions

Xospita 40mg may interact with other medications, including certain antibiotics, antifungals, and herbal supplements. Grapefruit products can affect how the drug works. Avoid alcohol unless approved by your healthcare provider. Inform your doctor about all prescription, over-the-counter, and complementary medicines you are taking.

Frequently Asked Questions

Xospita 40mg is used to treat adults with relapsed or refractory acute myeloid leukemia (AML) that has a FLT3 mutation.

Store Xospita 40mg tablets at room temperature in their original packaging, away from moisture and direct sunlight.

Xospita 40mg may interact with other medications; consult your healthcare provider before combining treatments.

Common side effects include fatigue, nausea, and changes in taste, though these vary by individual.

Xospita 40mg helps manage symptoms and slow disease progression but is not a cure for AML.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.